Centocor Inc. has granted Mallinckrodt Medical Inc. exclusiverights to market and sell its diagnostic radiopharmaceuticalMyoscint in Europe, the Middle East and Africa, Centocorannounced on Thursday. The terms of the agreement were notdisclosed.
The diagnostic can be used for detection of myocardial necrosisthat occurs after heart attacks when it is combined withIndium-111. Myoscint has received regulatory approval inmost European countries but has faced a setback in the U.S. InMay, Centocor (NASDAQ:CNTO) withdrew a product licenseapplication (PLA) for Myoscint, citing "certain deficiencies" inthe application. At the same time, Centocor withdrew its PLAfor Fibriscint, a blood-clot imaging agent. At the time, theMalvern, Pa., company said it intended to submit a revised PLAfor Myoscint but would have to go back to the clinic to getmore data on Fibriscint.-- Brenda Sandburg
(c) 1997 American Health Consultants. All rights reserved.